Welcome to our dedicated page for HAEMONETICS SEC filings (Ticker: HAE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HAEMONETICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HAEMONETICS's regulatory disclosures and financial reporting.
Haemonetics Corporation entered into a non-exclusive supply agreement with CSL Plasma Inc. under which CSL may use Haemonetics’ NexSys PCS® devices with Persona® PLUS technology and purchase related disposables for U.S. plasma collection centers. The agreement does not include minimum purchase commitments, and Haemonetics currently expects CSL to transition only a portion of its U.S. centers, with the scope and timing of that transition still undetermined. Because of this uncertainty, Haemonetics is not revising its fiscal 2027 guidance at this time and plans to discuss the anticipated financial impact of the agreement in conjunction with its second fiscal quarter earnings call in November 2026.
AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC reported beneficial ownership of 2,266,489 shares of Haemonetics Corp common stock, representing 4.99% of the class as of 06/30/2026. Both entities report shared voting power over 2,149,735 shares and shared dispositive power over 2,266,489 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC.
Haemonetics Corporation reported first-quarter fiscal 2027 net revenues of 339,380 (Dollars in Thousands), up 5.6% compared with the same period a year earlier. Operating income rose 6.7% to 57,458, while net income declined 3.0% to 33,010 and diluted EPS increased 2.9% to $0.72.
Apheresis net revenues grew 5.3%, led by volume growth and share gains in Plasma, and MedSurg revenues increased 6.0% on strength in Vascular Closure and Hemostasis Management. Gross margin remained 59.8%, supported by a shift toward higher-margin offerings and the absence of prior-year inventory fair value step-up amortization.
Net cash provided by operating activities improved to 52,323 from 17,395 (Dollars in Thousands). Cash and cash equivalents were 223,384 against total debt of 1,174,158. During fiscal 2026, the company repurchased 3,009,834 shares for $175.0 million under its 2025 program, leaving $325.0 million authorized as of June 27, 2026.
Haemonetics reported first quarter fiscal 2027 revenue of $339.4 million, up 5.6% year over year with 5.9% organic growth. Apheresis revenue was $191.3 million and MedSurg revenue $148.1 million, both growing mid‑single digits, led by Plasma and Blood Management Technologies, while Interventional Technologies also returned to growth.
GAAP gross margin held at 59.8%. Operating income was $57.5 million with a 16.9% margin. Net income was $33.0 million and earnings per diluted share $0.72, slightly above $0.70 a year earlier despite a higher tax rate of 30.6%. Adjusted EPS was $1.14 on a 23.4% adjusted operating margin.
Cash flow from operating activities rose to $52.3 million and free cash flow to $39.1 million, supporting a cash balance of $223.4 million. Management raised fiscal 2027 guidance to 5–8% reported revenue growth and 4–7% organic growth, with 50–100 basis points of adjusted operating margin expansion and free cash flow conversion of about 80%.
Madaus Martin D reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Martin D. Madaus received a grant of 2,538 restricted stock units under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan on July 24, 2026. The RSUs vest 100% on the first anniversary of the grant date, with each unit delivering one share of common stock and 2,538 shares reported as directly owned after the award.
Zane Ellen M reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corporation director Ellen M. Zane received a grant of 2,538 restricted stock units under the company’s Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, and her direct common stock holdings total 21,911 shares after the award.
Pomeroy Claire reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Claire Pomeroy reported a grant of 2,538 restricted stock units (RSUs) under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan on 2026-07-24. The RSUs vest 100% on the first anniversary of the grant date, with each RSU delivering one share of common stock upon vesting. After this award, her direct holdings total 19,410 shares of common stock.
KROLL MARK W reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Mark W. Kroll reported an equity award of 2,538 restricted stock units (RSUs) granted under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, with each RSU representing a contingent right to receive one (1) share of common stock when vested. Following this award, his reported direct holdings are 27,295 common shares, including these RSUs.
Haemonetics Corp director Lloyd Emerson Johnson reported an equity compensation award of 2,538 shares of common stock in the form of restricted stock units (RSUs) on 2026-07-24. The RSUs vest 100% on the first anniversary of the grant date, with each RSU converting into one share of common stock when vested.
After this grant, Johnson’s directly held common stock position was reported as 15,471 shares.
COYLE MICHAEL J reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corp director Michael J. Coyle received an equity award of 2,538 restricted stock units (RSUs) tied to the company’s common stock on 2026-07-24 under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, with each RSU representing a contingent right to receive one share of common stock when vested. Following this award, Coyle directly holds 17,932 shares of Haemonetics common stock.